Pfizer Inc., the leading global pharmaceutical company, has received a Neutral rating from UBS.

The majority of Pfizer's net sales come from its primary care products, which make up 52.3% of total sales. These products include internal medicine medications, vaccines, treatments for Covid-19, antivirals, and mRNA-based products.

Specialty care products contribute 25.6% of sales and focus on immunology, hospital treatments, and rare diseases. Oncology products account for 19.9% of sales, while the remaining 2.2% falls under other product categories.

In terms of geographical distribution, Pfizer's sales are divided with 42.3% coming from the United States, 21.9% from Europe, and 33.8% from other regions, indicating the company's diverse market presence.